Taselisib

DB12108InvestigationalSmall molecule

Taselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.

Formula / weight: C₂₄H₂₈N₈O₂ · 460.542 g/mol (avg)
Code names: GDC-0032 · RG-7604 · RO5537381

Resolves to

Compound

UNIIL08J2O299MCAS1282512-48-4ChEMBLCHEMBL2387080PubChem51001932

Clinical / RWD

PharmGKBPA166163227

Structure

InChIKeyBEUQXVWXFDOSAQ-UHFFFAOYSA-NSMILESCC(C)N1N=C(C)N=C1C1=CN2CCOC3=CC(=CC=C3C2=N1)C1=CN(N=C1)C(C)(C)C(N)=O

Targets

P48736PIK3CGP42336PIK3CA

What you can answer from here — as of May 26, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

16Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Taselisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account